2021 Review & 2022 Trend of China pharmaceutical industry
- 2021 Policy review of China pharmaceutical industry
- 2021 China pharmaceutical industry events
- 2021 China blockbuster innovative drugs approved
- 2022 China pharmaceutical industry development trend
- Guest speaker：Roadshow of the innovative asset to treat lung diseases – IPF (Idiopathic pulmonary fibrosis)
Event details
|
DATE Wednesday Jan 19th, 2022 VENUE Online Webex / Zoom TIME 10:00 – 11:00 Berlin time (CET) 16:00 – 17:00 Beijing time (GMT+8) RSVP This is a complimentary event VIP tickets priority for Lingmed current clients Please RSVP by Jan 18th, 2022 |
PRESENTERS Lingling Cao, CEO & Founder Dr Hank Wang, Medical advisor Guest speaker REGISTER +86 21 5386 3003 BD@lingmed.net |
Agenda
| CET 10:00 - 10:30 |
– 2021 Policy review of China pharmaceutical industry – 2021 Global & China pharmaceutical industry events – 2021 Global & China blockbuster innovative drugs approved – 2022 China pharmaceutical industry development trend |
by Dr Hank Wang (Chinese) |
| CET 10:30 - 10:35 | Linkedbio services & projects introductions | by Lingling Cao (English) |
| CET 10:35 - 10:55 | Roadshow of the innovative asset to treat lung diseases – IPF (Idiopathic pulmonary fibrosis) | by Guest speaker (English) |
| CET 10:55 – 11:00 | Q&A | (English & Chinese) |
Presenters
 |
Hank Wang Medical advisor Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market |
 |
Lingling Cao CEO & Founder Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany |